TSE:ASP - Acerus Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Acerus Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Today's Range N/A50-Day RangeC$0.06MA: C$0.07▼C$0.0852-Week Range N/AVolume90,500 shsAverage Volume81,773 shsMarket CapitalizationC$20.90 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartEarningsInsider TradesHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. Read More… Industry, Sector and Symbol Stock Exchange TSE Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolTSE:ASP Previous Symbol CUSIPN/A CIKN/A Webhttp://www.aceruspharma.com/ Phone416-679-0771Debt Debt-to-Equity Ratio105.08 Current Ratio0.89 Quick Ratio0.59Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesC$5.32 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow5.00 Book ValueC($0.03) per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees29 Outstanding Shares261,225,000Market CapC$20.90 million Next Earnings Date3/3/2020 (Estimated) OptionableNot Optionable Receive ASP News and Ratings via Email Sign-up to receive the latest news and ratings for ASP and its competitors with MarketBeat's FREE daily newsletter. TSX:ASP Rates by TradingView Acerus Pharmaceuticals (TSE:ASP) Frequently Asked Questions What is Acerus Pharmaceuticals' stock symbol? Acerus Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ASP." How were Acerus Pharmaceuticals' earnings last quarter? Acerus Pharmaceuticals Co. (TSE:ASP) announced its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.02) earnings per share for the quarter. The business had revenue of ($0.22) million for the quarter. View Acerus Pharmaceuticals' Earnings History. When is Acerus Pharmaceuticals' next earnings date? Acerus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Acerus Pharmaceuticals. Has Acerus Pharmaceuticals been receiving favorable news coverage? News coverage about ASP stock has been trending somewhat negative recently, InfoTrie reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Acerus Pharmaceuticals earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Acerus Pharmaceuticals. Who are some of Acerus Pharmaceuticals' key competitors? Some companies that are related to Acerus Pharmaceuticals include Biosyent (RX), Invion (IVX), Science in Sport (SIS), InMed Pharmaceuticals (IN), MMJ Group (MMJ), Pediapharm (MDP), Eve & Co Inc (EVE), Zomedica Pharmaceuticals (ZOM), MGC Pharmaceuticals (MXC), Viridium Pacific Group (VIR), Harvest One Cannabis (HVT), cbdMD (YCBD), Venture Life Group (VLG), Cipher Pharmaceuticals (CPH) and Diurnal Group (DNL). What other stocks do shareholders of Acerus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acerus Pharmaceuticals investors own include Aurora Cannabis (ACB), Surna (SRNA), Allena Pharmaceuticals (ALNA), Molecular Templates (MTEM), Avid Bioservices (CDMO), OHR Pharmaceutical (OHRP), Trilogy International Partners (TRL), Ritter Pharmaceuticals (RTTR), Sorrento Therapeutics (SRNE) and Algonquin Power & Utilities (AQN). Who are Acerus Pharmaceuticals' key executives? Acerus Pharmaceuticals' management team includes the folowing people: Dr. Nathan Bryson, Chief Scientific OfficerMr. Philippe Savard, VP, Gen. Counsel & Corp. Sec.Mr. Edward Gudaitis, Pres , CEO & DirectorMr. Robert M. Motz, Chief Financial OfficerMr. Hubert Tomasz Czerwinski, Pres of Acerus Pharmaceuticals SRL How do I buy shares of Acerus Pharmaceuticals? Shares of ASP and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab. How big of a company is Acerus Pharmaceuticals? Acerus Pharmaceuticals has a market capitalization of C$0.00 and generates C$5.32 million in revenue each year. Acerus Pharmaceuticals employs 29 workers across the globe.View Additional Information About Acerus Pharmaceuticals. What is Acerus Pharmaceuticals' official website? The official website for Acerus Pharmaceuticals is http://www.aceruspharma.com/. How can I contact Acerus Pharmaceuticals? The company can be reached via phone at 416-679-0771. MarketBeat Community Rating for Acerus Pharmaceuticals (TSE ASP)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 117 (Vote Outperform)Underperform Votes: 120 (Vote Underperform)Total Votes: 237MarketBeat's community ratings are surveys of what our community members think about Acerus Pharmaceuticals and other stocks. Vote "Outperform" if you believe ASP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/27/2020 by MarketBeat.com StaffFeatured Article: How prevalent are 12b-1 fees?
